Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Blood|August 18, 2012
Targeting oncogenic Ras signaling in hematologic malignanciesAshley F Ward, Benjamin S Braun, Kevin M ShannonBlood|May 3, 2013
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivoAngell Shieh, Ashley F Ward, Kegan L Donlan, et al.Oncotarget|March 22, 2018
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLLJohn C Byrd, Stephen Smith, Nina Wagner-Johnston, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2020
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic AnalysisKelly J Norsworthy, Flora Mulkey, Emma C Scott, et al.Oncotarget|June 21, 2019
Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLLJohn C Byrd, Stephen Smith, Nina Wagner-Johnston, et al.Pediatric Blood & Cancer|February 24, 2015
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology GroupElliot Stieglitz, Ashley F Ward, Robert B Gerbing, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2020
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public WorkshopKristen L Mueller, Marc R Theoret, Steven J Lemery, et al.Pageof 1